Characteristics of patients diagnosed with both melanoma and renal cell cancer

Cancer Causes and Control

Volumn 24, Issue 11, 2013, Pages 1925-1933

  Abern, Michael R ^a   Tsivian, Matvey ^a   Coogan, Christopher L ^b   Kaufman, Howard L ^b   Polascik, Thomas J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Histology; Incidence; Melanoma; Renal cell carcinoma; SEER

Indexed keywords

ADULT; AGED; AGING; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PATIENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; EYE CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; SEX DIFFERENCE;

AGED; CARCINOMA, RENAL CELL; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; LINEAR MODELS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; UNITED STATES;

EID: 84886779657     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0267-0     Document Type: Article

References (25)

1. Howlader NNA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK SEER Cancer Statistics Review, 1975-2008. Available from URL: http://seer.cancer.gov/csr/1975-2008/
2. Navai N, Wood CG (2012) Environmental and modifiable risk factors in renal cell carcinoma. Urol Oncol 30:220-224
3. Park SL, Le Marchand L, Wilkens LR et al (2012) Risk factors for malignant melanoma in white and non-white/non-African American populations: the multiethnic cohort. Cancer Prev Res 5:423-434
4. Stinauer MA, Kavanagh BD, Schefter TE et al (2011) Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol 6:34
5. Cesana GC, DeRaffele G, Cohen S et al (2006) Characterization of CD4 + CD25 + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24:1169-1177
6. Bracarda S, Eggermont AMM, Samuelsson J (2010) Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer 46:284-297
7. Sabatino M, Kim-Schulze S, Panelli MC et al (2009) Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 27:2645-2652
8. Abdel-Rahman MH, Boru G, Massengill J, Salem MM, Davidorf FH (2010) MET oncogene inhibition as a potential target of therapy for uveal melanomas. Invest Ophthalmol Vis Sci 51:3333-3339
9. Lindor NM, Dechet CB, Greene MH et al (2001) Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test 5:101-106
10. Lubensky IA, Schmidt L, Zhuang Z et al (1999) Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 155:517-526
11. Parrella P, Fazio VM, Gallo AP, Sidransky D, Merbs SL (2003) Fine mapping of chromosome 3 in uveal melanoma. Cancer Res 63:8507-8510
12. Puri N, Ahmed S, Janamanchi V et al (2007) c-Met Is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13:2246-2253
13. Bertolotto C, Lesueur F, Giuliano S et al (2011) A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480:94-98
14. Crocetti E, Guzzinati S, Paci E, et al (2008) The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of Cancer Registries). Melanoma Res 18:230-234. doi: 10.1097/CMR.0b013e3282fafd0a
15. Wu Y-H, Kim GH, Wagner JD, Hood AF, Chuang T-Y (2006) The association between malignant melanoma and noncutaneous malignancies. Int J Dermatol 45:529-534
16. Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M (2001) Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol 145:981-985
17. Bradford PT, Freedman DM, Goldstein AM, Tucker MA (2010) Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 146:265-272
18. Beisland C, Talleraas O, Bakke A, Norstein J (2006) Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int 97:698-702
19. Chakraborty S, Tarantolo SR, Batra SK, Hauke RJ (2012) Incidence and Prognostic Significance of Second Primary Cancers in Renal Cell Carcinoma. Am J Clin Oncol 36(2):132-142
20. Maubec E, Chaudru V, Mohamdi H et al (2010) Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer 116:5716-5724
21. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Research Data, Nov 2010 Sub (1973-2008) < Katrina/Rita Population Adjustment > - Linked To County Attributes - Total U.S., 1969-2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission
22. Sahai H, Khurshid A (1993) Confidence intervals for the mean of a Poisson distribution: a review. Biometr J 35:857-867
23. Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154
24. Sennino B, Ishiguro-Oonuma T, Wei Y et al (2012) Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2:270-287
25. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr (eds) (2006) New malignancies among cancer survivors: SEER cancer registries, 1973-2000. National Cancer Institute, Bethesda, MD